Shopping Cart
- Remove All
- Your shopping cart is currently empty
Description | Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease. |
Targets&IC50 | JAK3:9.5(pKi), JAK2:8.8 (pKi), JAK1:10.0(pKi) |
In vitro | Izencitinib ( TD-1473 ), as an effective inhibitor of JAK1, JAK2 and JAK3, can act on the human JAK kinase domain ( pKi values are 10.0,8.8 and 9.5, respectively )[1]. |
In vivo | Izencitinib ( TD-1473,1 mg / kg BID ) can be used in oxazolone-induced colitis in mice[1]. |
Alias | TD-1473, JNJ-8398 |
Molecular Weight | 402.50 |
Formula | C22H26N8 |
Cas No. | 2051918-33-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 30 mg/mL (74.53 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.